Hemostemix Announces First Sales Orders for ACP-01
Hemostemix (HMTXF) has announced its first sales orders for ACP-01 Treatments following a social media campaign and presentations in Puerto Rico. The company has secured initial signed commitments amounting to $400,000 for 2025, with 11 months of selling ahead.
The company's CEO, Thomas Smeenk, highlighted that advanced sales help patients understand their treatment sequence and enable efficient scheduling of physician time and production. During recent meetings with physicians who have treated approximately 200 patients with ACP-01, an invasive cardiologist emphasized the unique effectiveness of ACP-01 in rebuilding heart function, stating it outperforms other autologous stem cell products specifically for cardiac applications.
Hemostemix (HMTXF) ha annunciato i primi ordini di vendita per i trattamenti ACP-01 grazie a una campagna sui social media e presentazioni a Porto Rico. L'azienda ha ottenuto impegni firmati iniziali per un importo di 400.000 dollari per il 2025, con 11 mesi di vendite davanti a sé.
Il CEO dell'azienda, Thomas Smeenk, ha sottolineato che le vendite anticipate aiutano i pazienti a comprendere la sequenza dei loro trattamenti e permettono una programmazione efficiente del tempo dei medici e della produzione. Durante recenti incontri con medici che hanno trattato circa 200 pazienti con ACP-01, un cardiologo invasivo ha messo in evidenza l'efficacia unica di ACP-01 nel ripristinare la funzionalità cardiaca, affermando che supera altri prodotti di cellule staminali autologhe specificamente per applicazioni cardiache.
Hemostemix (HMTXF) ha anunciado sus primeros pedidos de ventas para los tratamientos ACP-01 después de una campaña en redes sociales y presentaciones en Puerto Rico. La empresa ha asegurado compromisos firmados iniciales por un total de 400.000 dólares para 2025, con 11 meses de ventas por delante.
El CEO de la empresa, Thomas Smeenk, destacó que las ventas anticipadas ayudan a los pacientes a entender la secuencia de su tratamiento y permiten una programación eficiente del tiempo de los médicos y de la producción. Durante recientes reuniones con médicos que han tratado a aproximadamente 200 pacientes con ACP-01, un cardiólogo invasivo enfatizó la eficacia única de ACP-01 en la reconstrucción de la función cardíaca, afirmando que supera a otros productos de células madre autólogas específicamente para aplicaciones cardíacas.
Hemostemix (HMTXF)는 푸에르토리코에서의 소셜 미디어 캠페인과 프레젠테이션 이후 ACP-01 치료에 대한 첫 번째 판매 주문을 발표했습니다. 회사는 2025년을 위한 400,000달러의 초기 서명 약속을 확보했으며, 앞으로 11개월의 판매가 남아 있습니다.
회사의 CEO인 Thomas Smeenk는 선진 판매가 환자들이 치료 순서를 이해하는 데 도움을 주고 의사의 시간과 생산을 효율적으로 계획하는 데 기여한다고 강조했습니다. ACP-01로 약 200명의 환자를 치료한 의사와의 최근 회의에서, 한 침습적 심장 전문의는 ACP-01이 심장 기능을 재건하는 데 있어 독특한 효과를 발휘하며 특정 심장 응용 분야에서 다른 자가 줄기 세포 제품보다 우수하다고 강조했습니다.
Hemostemix (HMTXF) a annoncé ses premières commandes de vente pour les traitements ACP-01 suite à une campagne sur les réseaux sociaux et des présentations à Porto Rico. L'entreprise a sécurisé des engagements signés initiaux d'un montant de 400 000 dollars pour 2025, avec 11 mois de ventes à venir.
Le PDG de l'entreprise, Thomas Smeenk, a souligné que les ventes anticipées aident les patients à comprendre la séquence de leur traitement et permettent une planification efficace du temps médecin et de la production. Lors de récents rendez-vous avec des médecins ayant traité environ 200 patients avec ACP-01, un cardiologue invasif a souligné l'efficacité unique d'ACP-01 dans la reconstruction de la fonction cardiaque, affirmant qu'il surpasse d'autres produits de cellules souches autologues spécifiquement pour des applications cardiaques.
Hemostemix (HMTXF) hat seine ersten Verkaufsaufträge für ACP-01-Behandlungen nach einer Social-Media-Kampagne und Präsentationen in Puerto Rico bekannt gegeben. Das Unternehmen hat erste unterschriebene Verpflichtungen in Höhe von 400.000 Dollar für 2025 gesichert, mit 11 Monaten Verkaufszeit vor sich.
Der CEO des Unternehmens, Thomas Smeenk, hob hervor, dass fortgeschrittene Verkäufe den Patienten helfen, ihre Behandlung zu verstehen und eine effiziente Planung der Zeit der Ärzte und der Produktion zu ermöglichen. Bei jüngsten Meetings mit Ärzten, die etwa 200 Patienten mit ACP-01 behandelt haben, betonte ein invasiver Kardiologe die einzigartige Wirksamkeit von ACP-01 bei der Wiederherstellung der Herzfunktion und stellte fest, dass es andere autologe Stammzellprodukte speziell für kardiologische Anwendungen übertrifft.
- Secured initial sales commitments worth $400,000
- Positive clinical feedback from physicians who treated 200 patients
- Demonstrated superior efficacy in cardiac applications compared to other stem cell products
- Current sales numbers described as 'modest'
Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments are gaining traction, following its social media campaign and presentations in Puerto Rico.
"Advanced sales of ACP-01 enables the purchaser/patient to understand if they are patient one, 10, or 500, and that certainty is helpful," stated Thomas Smeenk, Hemostemix, CEO. "Advanced sales enables Hemostemix to schedule the physician's time and schedule production time. While our numbers are modest at this point, the first signed commitments amount to some
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal, and cardiomyocyte cell precursors, to treat no-option patients worldwide.
Learn more: www.hemostemix.com
Contact: Thomas Smeenk, President & CEO - tsmeenk@hemostemix.com | (905) 580-4170
Stock Information: (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0)
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238886
FAQ
How much are the initial sales commitments for Hemostemix (HMTXF) ACP-01 in 2025?
How many patients have been treated with Hemostemix (HMTXF) ACP-01 according to the recent announcement?
What are the clinical advantages of HMTXF's ACP-01 for heart treatment?
How does Hemostemix (HMTXF) manage its ACP-01 treatment scheduling?
